Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants

André B P van Kuilenburg; Marjolein C H Pleunis-van Empel; Rick B Brouwer; Angelique E J Sijben; Daan G Knapen; Thijs H Oude Munnink; Jelmer J van Zanden; Jenny Janssens-Puister; Doreen Dobritzsch; Rutger Meinsma; Judith Meijer-Jansen; Silvy J M van Dooren; Raymon Vijzelaar; Ana Pop; Gajja S Salomons; Jan Gerard Maring; Klary E Niezen-Koning

doi:10.1200/PO.23.00599

Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants

André B P van Kuilenburg^*, Marjolein C H Pleunis-van Empel, Rick B Brouwer, Angelique E J Sijben, Daan G Knapen, Thijs H Oude Munnink, Jelmer J van Zanden, Jenny Janssens-Puister, Doreen Dobritzsch, Rutger Meinsma, Judith Meijer-Jansen, Silvy J M van Dooren, Raymon Vijzelaar, Ana Pop, Gajja S Salomons, Jan Gerard Maring, Klary E Niezen-Koning

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

60 Downloads (Pure)

Abstract

A DPD deficiency should be considered in case of severe toxicity even in the absence of common risk variants in DPYD.

Original language	English
Article number	e2300599
Number of pages	7
Journal	JCO Precision Oncology
Volume	8
Early online date	6-May-2024
DOIs	https://doi.org/10.1200/PO.23.00599
Publication status	Published - Sept-2024

Keywords

Humans
Dihydropyrimidine Dehydrogenase Deficiency/genetics
Capecitabine/adverse effects
Dihydrouracil Dehydrogenase (NADP)/genetics
Antimetabolites, Antineoplastic/adverse effects
Male
Female
Fatal Outcome
Middle Aged

Access to Document

10.1200/PO.23.00599

Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD VariantsFinal publisher's version, 796 KBLicence: Taverne

Handle.net

Persistent link

Cite this

van Kuilenburg, A. B. P., Pleunis-van Empel, M. C. H., Brouwer, R. B., Sijben, A. E. J., Knapen, D. G., Oude Munnink, T. H., van Zanden, J. J., Janssens-Puister, J., Dobritzsch, D., Meinsma, R., Meijer-Jansen, J., van Dooren, S. J. M., Vijzelaar, R., Pop, A., Salomons, G. S., Maring, J. G., & Niezen-Koning, K. E. (2024). Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants. JCO Precision Oncology, 8, Article e2300599. https://doi.org/10.1200/PO.23.00599

@article{34a4f97c1a9c42f98b8bb30caf7a95a8,

title = "Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants",

abstract = "A DPD deficiency should be considered in case of severe toxicity even in the absence of common risk variants in DPYD.",

keywords = "Humans, Dihydropyrimidine Dehydrogenase Deficiency/genetics, Capecitabine/adverse effects, Dihydrouracil Dehydrogenase (NADP)/genetics, Antimetabolites, Antineoplastic/adverse effects, Male, Female, Fatal Outcome, Middle Aged",

author = "{van Kuilenburg}, {Andr{\'e} B P} and {Pleunis-van Empel}, {Marjolein C H} and Brouwer, {Rick B} and Sijben, {Angelique E J} and Knapen, {Daan G} and {Oude Munnink}, {Thijs H} and {van Zanden}, {Jelmer J} and Jenny Janssens-Puister and Doreen Dobritzsch and Rutger Meinsma and Judith Meijer-Jansen and {van Dooren}, {Silvy J M} and Raymon Vijzelaar and Ana Pop and Salomons, {Gajja S} and Maring, {Jan Gerard} and Niezen-Koning, {Klary E}",

year = "2024",

month = sep,

doi = "10.1200/PO.23.00599",

language = "English",

volume = "8",

journal = "JCO Precision Oncology",

issn = "2473-4284",

publisher = "AMER SOC CLINICAL ONCOLOGY",

}

van Kuilenburg, ABP, Pleunis-van Empel, MCH, Brouwer, RB, Sijben, AEJ, Knapen, DG , Oude Munnink, TH, van Zanden, JJ, Janssens-Puister, J, Dobritzsch, D, Meinsma, R, Meijer-Jansen, J, van Dooren, SJM, Vijzelaar, R, Pop, A, Salomons, GS, Maring, JG & Niezen-Koning, KE 2024, 'Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants', JCO Precision Oncology, vol. 8, e2300599. https://doi.org/10.1200/PO.23.00599

TY - JOUR

T1 - Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants

AU - van Kuilenburg, André B P

AU - Pleunis-van Empel, Marjolein C H

AU - Brouwer, Rick B

AU - Sijben, Angelique E J

AU - Knapen, Daan G

AU - Oude Munnink, Thijs H

AU - van Zanden, Jelmer J

AU - Janssens-Puister, Jenny

AU - Dobritzsch, Doreen

AU - Meinsma, Rutger

AU - Meijer-Jansen, Judith

AU - van Dooren, Silvy J M

AU - Vijzelaar, Raymon

AU - Pop, Ana

AU - Salomons, Gajja S

AU - Maring, Jan Gerard

AU - Niezen-Koning, Klary E

PY - 2024/9

Y1 - 2024/9

N2 - A DPD deficiency should be considered in case of severe toxicity even in the absence of common risk variants in DPYD.

AB - A DPD deficiency should be considered in case of severe toxicity even in the absence of common risk variants in DPYD.

KW - Humans

KW - Dihydropyrimidine Dehydrogenase Deficiency/genetics

KW - Capecitabine/adverse effects

KW - Dihydrouracil Dehydrogenase (NADP)/genetics

KW - Antimetabolites, Antineoplastic/adverse effects

KW - Male

KW - Female

KW - Fatal Outcome

KW - Middle Aged

U2 - 10.1200/PO.23.00599

DO - 10.1200/PO.23.00599

M3 - Article

C2 - 38709992

SN - 2473-4284

VL - 8

JO - JCO Precision Oncology

JF - JCO Precision Oncology

M1 - e2300599

ER -

Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this